Zollinger‑Ellison type gastrinomas (multiple endocrine neoplasia type 1) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Type Gastrinomas (Multiple Endocrine Neoplasia Type 1) – Complete Guide

Zollinger‑Ellison Type Gastrinomas (Multiple Endocrine Neoplasia Type 1)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder caused by gastrin‑secreting tumors (gastrinomas) that lead to excessive gastric acid production. When these gastrinomas arise in the context of Multiple Endocrine Neoplasia type 1 (MEN‑1), the condition is often called Zollinger‑Ellison type gastrinoma associated with MEN‑1. MEN‑1 is an inherited cancer‑predisposition syndrome characterized by tumors of the parathyroid glands, pancreatic‑islet cells, and anterior pituitary.

  • Who it affects: Both men and women; onset typically in the 3rd–5th decade of life. Approximately 20–30 % of patients with MEN‑1 develop gastrinomas, and up to 80 % of ZES cases are linked to MEN‑1.[1][2]
  • Prevalence: Gastrinomas are the most common functional pancreatic neuroendocrine tumors, with an incidence of about 1–3 cases per million per year. MEN‑1 occurs in roughly 1 in 30,000 individuals worldwide.[3][4]
  • Genetics: MEN‑1 is autosomal dominant, caused by pathogenic variants in the MEN1 tumor‑suppressor gene located on chromosome 11q13. A single mutated allele is inherited; a second somatic hit leads to tumor formation.

Symptoms

Symptoms result from two overlapping mechanisms: (1) hyperacidic gastric environment caused by excess gastrin, and (2) mass effect or hormonal activity of the tumor itself. People with MEN‑1 may also have symptoms from other endocrine tumors.

Gastro‑intestinal manifestations

  • Peptic ulcer disease (PUD): Multiple, refractory ulcers in the duodenum or jejunum; often >3 cm and may be atypically located.
  • Abdominal pain: Burning or gnawing pain that improves with meals or antacids.
  • Diarrhea: Acidic chyme irritates the small intestine, producing watery, foul‑smelling stools; may occur several times daily.
  • Steatorrhea (fatty stools): Malabsorption due to acid inactivation of pancreatic enzymes.
  • Nausea & vomiting: Can be precipitated by ulcer pain or gastric outlet obstruction.
  • Gastro‑intestinal bleeding: Hematemesis or melena from ulcer erosion.

Systemic and MEN‑1‑related symptoms

  • Hyperparathyroidism: Kidney stones, bone pain, fatigue, and elevated calcium.
  • Pituitary adenomas: Visual field defects, headaches, galactorrhea, or hormonal excess (e.g., prolactinoma).
  • Weight loss: Chronic malabsorption and high metabolic demand.
  • Fatigue & anemia: Chronic blood loss or nutritional deficiencies.

Causes and Risk Factors

Primary cause

The root cause is a pathogenic mutation in the MEN1 gene, which encodes menin, a protein that regulates cell growth and DNA repair. Loss of functional menin predisposes pancreatic‑islet cells to become gastrin‑producing neuroendocrine tumors.

Risk factors

  • Family history: First‑degree relative with MEN‑1 confers a 50 % chance of inheriting the mutation.
  • Age: Penetrance increases with age; most gastrinomas present before 50 years.
  • Gender: Slight female predominance in some series, but overall risk is similar.
  • Other endocrine neoplasias: Presence of hyperparathyroidism or pituitary tumor raises suspicion for MEN‑1.
  • Environmental factors: No specific lifestyle factors have been linked, but chronic H. pylori infection may worsen ulcer disease.

Diagnosis

Diagnosis combines clinical suspicion, biochemical testing, imaging, and sometimes genetic analysis.

Biochemical tests

  1. Fasting serum gastrin: Levels >1000 pg/mL (10× upper limit) in the presence of low gastric pH are diagnostic. [5]
  2. Secretin stimulation test: A >120 pg/mL rise in gastrin after IV secretin is highly specific for gastrinoma.
  3. Acid output measurement: 24‑hour gastric acid collection shows hypersecretion (>15 mEq/hour).
  4. MEN1 genetic testing: Sequencing of the MEN1 gene confirms hereditary predisposition; recommended for all patients with ZES and a family history.

Imaging studies

  • Endoscopic ultrasound (EUS): Detects small pancreatic or duodenal lesions (<1 cm).
  • Multiphasic contrast‑enhanced CT or MRI: Provides anatomical detail and assesses metastatic spread (liver, lymph nodes).
  • Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT: Highly sensitive for neuroendocrine tumors and guides surgical planning.
  • Selective arterial secretagogue injection (SASI) test: Localizes gastrinoma when non‑invasive imaging is equivocal.

Endoscopic evaluation

Upper endoscopy identifies ulcer disease, takes biopsies to rule out Helicobacter pylori, and may visualize a submucosal tumor.

Treatment Options

Management aims to control acid hypersecretion, eradicate or control the tumor, and monitor for other MEN‑1 manifestations.

Medical therapy – controlling acid

  • Proton pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line; doses may be 2–4 times the standard adult dose, titrated to symptom control and gastrin levels.[6]
  • H2‑receptor antagonists: Used as adjuncts if PPI alone is insufficient.
  • Antacids: For breakthrough heartburn.

Surgical management

  1. Enucleation or limited resection: Preferred for solitary, well‑localized duodenal gastrinomas.
  2. Pancreaticoduodenectomy (Whipple procedure): Considered for multiple or invasive tumors, especially when adjacent to the pancreatic head.
  3. Debulking surgery: Reduces tumor burden and gastrin output when cure is unlikely.
  4. Liver metastasectomy or radiofrequency ablation: For isolated hepatic disease.

Because MEN‑1 gastrinomas are often multifocal, complete surgical cure is uncommon; the goal is symptom control and disease stabilization.[7]

Systemic therapies for unresectable or metastatic disease

  • Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin release and may shrink tumors.
  • Targeted therapy (everolimus, sunitinib): Approved for progressive pancreatic neuroendocrine tumors; benefit must be weighed against side effects.
  • Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE: Delivers targeted radiation to somatostatin‑receptor–positive lesions; shows durable disease control in 30‑40 % of patients.[8]
  • Cytotoxic chemotherapy: Reserved for high‑grade neuroendocrine carcinomas; regimens such as streptozocin‑5‑FU or temozolomide‑capecitabine.

Lifestyle and supportive measures

  • Dietary modifications: Small, low‑fat meals; avoid caffeine, alcohol, and spicy foods that stimulate acid.
  • Calcium & vitamin D supplementation: For those with hyperparathyroidism‑related bone loss.
  • Vaccinations: Hepatitis B and annual influenza for patients receiving systemic therapy.
  • Regular monitoring: Serum gastrin, calcium, renal function, and imaging every 6–12 months.

Living with Zollinger‑Ellison type Gastrinomas (MEN‑1)

Daily management tips

  1. Medication adherence: Take PPIs exactly as prescribed; missing doses can precipitate ulcer bleeding.
  2. Track symptoms: Keep a diary of pain, stool frequency, and any bleeding; share with your gastroenterologist.
  3. Nutrition:
    • Eat 5–6 small meals a day.
    • Prefer lean proteins, cooked vegetables, and low‑acid fruits (e.g., bananas, melons).
    • Limit high‑acid foods (citrus, tomatoes) and carbonated drinks.
  4. Hydration: Adequate fluids help prevent kidney stones if hyperparathyroidism is present.
  5. Screen for other MEN‑1 tumors: Annual eye exam for pituitary macroadenomas, serum calcium every 6 months, and periodic pituitary MRI.
  6. Psychosocial support: Join patient‐advocacy groups (e.g., MEN Network) for peer support and up‑to‑date information.
  7. Pregnancy considerations: Discuss medication safety with obstetrics; PPIs are generally safe, but surgical timing may be adjusted.

Prevention

Because MEN‑1 is genetic, primary prevention focuses on early detection rather than avoiding disease.

  • Genetic counseling: Offer testing to at‑risk relatives; cascade testing enables surveillance before symptoms develop.
  • Screening protocol for mutation carriers:
    • Start biochemical screening (fasting gastrin, calcium, PTH) at age 8–10.
    • Annual or biennial imaging (EUS, MRI) after puberty.
  • Helicobacter pylori eradication: While not a cause of gastrinoma, removing H. pylori reduces ulcer burden and may lessen complications.
  • Lifestyle: No specific habits prevent gastrinomas, but smoking cessation lowers overall cancer risk.

Complications

If uncontrolled, Zollinger‑Ellison type gastrinomas can lead to serious health issues.

  • Refractory peptic ulcer disease: Bleeding, perforation, or penetration requiring surgery.
  • Gastro‑intestinal bleeding: Chronic blood loss leads to iron‑deficiency anemia.
  • Malabsorption & nutritional deficiencies: Fat‑soluble vitamin (A, D, E, K) deficiency, osteoporosis.
  • Gastric outlet obstruction: From ulcer scarring or tumor mass effect.
  • Liver metastases: Occur in 30–50 % of MEN‑1 gastrinomas; can cause hepatic insufficiency.
  • Renal stones: Hypercalcemia from associated hyperparathyroidism.
  • Carcinoid‑type heart disease: Rare, but possible with extensive neuroendocrine tumor burden.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe abdominal pain that does not improve with antacids.
  • Vomiting of blood (hematemesis) or material that looks like coffee grounds.
  • Black, tarry stools (melena) indicating gastrointestinal bleeding.
  • Profuse, watery diarrhea leading to dehydration ( dizziness, rapid heartbeat, decreased urine output).
  • Sudden weakness, fainting, or confusion accompanied by rapid heart rate – possible severe blood loss or electrolyte imbalance.
  • Severe, persistent nausea and vomiting preventing you from keeping fluids down.

These signs may indicate ulcer perforation, massive bleeding, or a metabolic crisis and require immediate medical attention.

References

  1. Mayo Clinic. Zollinger‑Ellison syndrome. ©2023. Link
  2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Gastrinomas and MEN‑1. 2022. Link
  3. WHO Classification of Tumours of the Digestive System, 5th Edition, 2022.
  4. International MEN‑1 Consortium. Clinical practice guidelines for MEN‑1. Endocrine Reviews 2021;42(4): 647‑672.
  5. Wagenmakers MJ, et al. Diagnosis of Zollinger‑Ellison syndrome: role of secretin test. Gastroenterology 2020;158(5):1326‑1336.
  6. American College of Gastroenterology. ACG Clinical Guideline: Management of Peptic Ulcer Disease. 2023. Link
  7. Grant CS, et al. Surgical management of gastrinomas in MEN‑1 patients. Ann Surg 2021;273(2):264‑271.
  8. Strosberg J, et al. PRRT with 177Lu‑DOTATATE for neuroendocrine tumors: long‑term outcomes. J Clin Oncol 2022;40(12):1315‑1323.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References